Immunotherapeutics, as a treatment of human disease, has brought benefits to both patients and commercial success to many drug developers. However, determining the best experimental immunotherapy model is still a major obstacle toward answering questions like how to optimize the immuno-oncology agent to finally developing better treatments.
Based on the complexity of human disease, the selection of the experimental mice is the key to the study. Combining the in-depth knowledge of each model immunological features and detailed model construction strategy according to specific requirements results in highly human-relevant models for progressing the research.
Intending to help researchers quickly obtain valuable research animal models for human disease studies, Cyagen has established its drug development and screening platform through the combination of introduction and self-development in high-quality control - to serve research in cancer, immunity, endocrinology, cardiovascular disease (CVD), neurology, and infectious diseases. We offer various ready-to-use research mouse models and keep developing models and services for drug development and efficacy evaluation is now a high priority in our current R&D activities.
